These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 23337983

  • 1. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
    Takai T, Higaki K, Aguilar-Moncayo M, Mena-Barragán T, Hirano Y, Yura K, Yu L, Ninomiya H, García-Moreno MI, Sakakibara Y, Ohno K, Nanba E, Ortiz Mellet C, García Fernández JM, Suzuki Y.
    Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.
    Fantur KM, Wrodnigg TM, Stütz AE, Pabst BM, Paschke E.
    J Inherit Metab Dis; 2012 May; 35(3):495-503. PubMed ID: 22033734
    [Abstract] [Full Text] [Related]

  • 5. Structural basis of pharmacological chaperoning for human β-galactosidase.
    Suzuki H, Ohto U, Higaki K, Mena-Barragán T, Aguilar-Moncayo M, Ortiz Mellet C, Nanba E, Garcia Fernandez JM, Suzuki Y, Shimizu T.
    J Biol Chem; 2014 May 23; 289(21):14560-8. PubMed ID: 24737316
    [Abstract] [Full Text] [Related]

  • 6. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
    Kasperzyk JL, El-Abbadi MM, Hauser EC, D'Azzo A, Platt FM, Seyfried TN.
    J Neurochem; 2004 May 23; 89(3):645-53. PubMed ID: 15086521
    [Abstract] [Full Text] [Related]

  • 7. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
    Aguilar-Moncayo M, Takai T, Higaki K, Mena-Barragán T, Hirano Y, Yura K, Li L, Yu Y, Ninomiya H, García-Moreno MI, Ishii S, Sakakibara Y, Ohno K, Nanba E, Ortiz Mellet C, García Fernández JM, Suzuki Y.
    Chem Commun (Camb); 2012 Jul 04; 48(52):6514-6. PubMed ID: 22618082
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.
    Rigat BA, Tropak MB, Buttner J, Crushell E, Benedict D, Callahan JW, Martin DR, Mahuran DJ.
    Mol Genet Metab; 2012 Sep 04; 107(1-2):203-12. PubMed ID: 22784478
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
    Front S, Biela-Banaś A, Burda P, Ballhausen D, Higaki K, Caciotti A, Morrone A, Charollais-Thoenig J, Gallienne E, Demotz S, Martin OR.
    Eur J Med Chem; 2017 Jan 27; 126():160-170. PubMed ID: 27750150
    [Abstract] [Full Text] [Related]

  • 12. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J, Acosta W, Ayala J, Katta V, Flory A, Martin R, Radin J, Cramer CL, Radin DN.
    Mol Genet Metab; 2016 Feb 27; 117(2):199-209. PubMed ID: 26766614
    [Abstract] [Full Text] [Related]

  • 13. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
    Ohto U, Usui K, Ochi T, Yuki K, Satow Y, Shimizu T.
    J Biol Chem; 2012 Jan 13; 287(3):1801-12. PubMed ID: 22128166
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
    Yam GH, Bosshard N, Zuber C, Steinmann B, Roth J.
    Am J Physiol Cell Physiol; 2006 Apr 13; 290(4):C1076-82. PubMed ID: 16531566
    [Abstract] [Full Text] [Related]

  • 18. Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice.
    Kasperzyk JL, d'Azzo A, Platt FM, Alroy J, Seyfried TN.
    J Lipid Res; 2005 Apr 13; 46(4):744-51. PubMed ID: 15687347
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.